Supreme Court Hears Arguments on "Pay for Delay" Agreements

by Sheppard Mullin Richter & Hampton LLP
Contact

On March 25, 2012, the Supreme Court heard oral argument on the legality of “reverse payment” or “pay for delay” agreements between brand-name and generic drug manufacturers.

Reverse payment agreements settle patent infringement actions brought by a brand-name drug manufacturer against a potential generic competitor under the Hatch-Waxman Act. In contrast to typical settlements of patent infringement actions, it is the patent holder (the brand-name drug manufacturer) that agrees to pay a large sum of money to the accused infringer (the generic) in exchange for an agreement that the generic will not challenge the patent or enter the market for a period of time.

There is a circuit split on the test that courts apply in scrutinizing whether such agreements are anticompetitive. The Second, Eleventh and Federal Circuits have applied a “scope-of-the-patent” test. Under the “scope-of-the-patent” test, a reverse payment agreement is permitted so long as the terms of the agreement do not expand the exclusionary scope of the patent. For example, an agreement that would prohibit a generic from entering the market until after the patent’s expiration would be prohibited under the “scope-of-the-patent” test. The Third Circuit, however, has applied a “quick look” test under which reverse payment agreements are presumed anticompetitive unless proven otherwise. The Supreme Court granted certiorari in Federal Trade Commission v. Actavis to resolve this circuit split over the issue. Drug innovators generally advocate the “scope-of-the-patent” test, while the Federal Trade Commission (“FTC”) has argued for the more rigorous per se approach in which the burden is shifted onto the drug innovator to rebut the presumption that the settlement is anticompetitive.

Prior to the Supreme Court granting certiorari in Actavis, the 11th Circuit followed its own precedent and applied the “scope-of-the-patent” test. The 11th Circuit affirmed the dismissal of the FTC’s complaint, finding that the agreement in Actavis did not expand the scope of the patent at issue. Among other things, the agreement permitted the generic to enter the marketplace five years before the patent’s expiration, and the parties further agreed in a separate agreement that the generic would promote and share profits from the sales of the brand-name drug.

In the oral argument, the FTC opened by arguing that “a payment from one business to another in exchange for the recipient’s agreement not to compete is a paradigmatic antitrust violation,” and that “[r]everse payments to settle Hatch-Waxman suits are objectionable for the same reasons…[t]hey subvert the competitive process by giving generic manufacturers an incentive to accept a share of their rival’s monopoly profits as a substitute for actual competition…”

The justices did not appear to favor the FTC’s “quick look” test. Justice Breyer, along with Justice Sotomayor, suggested that district courts could resolve the question of whether a particular reverse payment settlement is anticompetitive by resort to the traditional antitrust “rule of reason” and that a shifting of the burden onto drug innovators to prove the agreement is not anticompetitive is unnecessary. Indeed, Justice Breyer expressed concerns that such a test would create an “administrative monster” in requiring the courts to decide whether or not the payments are for delay or something else. Justice Scalia took issue with the Hatch-Waxman Act itself, expressing concerns that understood antitrust principles should not be overturned “to patch up a mistake that Hatch-Waxman made.”

The justices also expressed concerns about adopting the opposing “scope-of-the-patent” test, which would, in essence, create a presumption of infringement by the generic product. Justice Sotomayor noted that settling an infringement action would create such a presumption – “I don’t know why we would be required to accept that there has or would be infringement by the product that has voluntarily decided not to pursue its rights.” The justices also expressed concerns that the financial incentives in adopting such a test would weigh in favor of settling cases, thereby reduce competition by generics, as the “scope-of-the-patent” test would in essence, incentivize brand name and generic manufacturers “in every single case . . . to split monopoly profits in this way to the detriment of all consumers.” Justice Kagan observed that “[i]t’s clear what’s going on here is that [the brand and generic firms are] splitting monopoly profits and the person who’s going to be injured are all the consumers out there.”

Stay tuned, as the Supreme Court is expected to issue its ruling before the end of its term in June 2013. This issue will have a significant impact on both brand-name and generic drug manufacturers as they consider their strategies on the transition from patent protection to generic competition. The decision will also likely have an impact for investors seeking to value pharmaceutical intellectual property. Sheppard Mullin attorneys can advise on these issues, including how to handle the uncertainty associated with the upcoming Supreme Court decision.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Sheppard Mullin Richter & Hampton LLP | Attorney Advertising

Written by:

Sheppard Mullin Richter & Hampton LLP
Contact
more
less

Sheppard Mullin Richter & Hampton LLP on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up using*

Already signed up? Log in here

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
Privacy Policy (Updated: October 8, 2015):
hide

JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.

Information Collection and Use by JD Supra

JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies.

The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.

If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.

Email Choice/Opt-out

Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.

Security

JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.

If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at info@jdsupra.com. In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.

Sharing and Disclosure of Information JD Supra Collects

Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.

In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.

Links to Other Websites

This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.

Changes in Our Privacy Policy

We reserve the right to change this Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our privacy policy will become effective upon posting of the revised policy on the Website. By continuing to use the Service or Website following such changes, you will be deemed to have agreed to such changes. If you do not agree with the terms of this Policy, as it may be amended from time to time, in whole or part, please do not continue using the Service or the Website.

Contacting JD Supra

If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at: info@jdsupra.com.

- hide
*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.